Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2020RMD OpenOpen Access

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

View Full Paper
Ask AI
Bookmark
Share

Authors

SCStanley CohenYTYoshiya TanakaXMXavier Mariette

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cohen et al. (2020) studied this question.

synapsesocial.com/papers/69dfedae60d9fa30ca7a10d5https://doi.org/10.1136/rmdopen-2020-001395
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tofacitinib versus Methotrexate in Rheumatoid Arthritis2014 · 785 citations
  2. 2Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources2016 · 43 citations